Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048971 · ClinicalTrials.gov registry record
Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy
A clinical trial of Colorectal Cancer and Diarrhea, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- 308
- Enrollment target
- 20
- Study locations
NCT00048971: Completed study of Colorectal Cancer and Diarrhea, sponsored by Alliance for Clinical Trials in Oncology.
NCT00048971 is a study of Colorectal Cancer and Diarrhea that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 308 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00048971, a study of Colorectal Cancer and Diarrhea, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- 308 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Genetic testing may help predict how patients will respond to chemotherapy drugs and may help doctors plan more effective treatment with fewer side effects. PURPOSE: Genetic study to determine how genes affect the severity of diarrhea in patients with stage III colon cancer who are receiving chemotherapy.
Conditions Studied
Interventions
- GENETIC mutation analysis
- GENETIC polymorphic microsatellite marker analysis
Study Locations (20)
California
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center - Los Angeles
- Veterans Affairs Medical Center - San Diego - San Diego
- UCSF Comprehensive Cancer Center - San Francisco
- Veterans Affairs Medical Center - San Francisco - San Francisco
Florida
- Broward General Medical Center - Fort Lauderdale
- Memorial Regional Hospital Comprehensive Cancer Center - Hollywood
- CCOP - Mount Sinai Medical Center - Miami Beach
- Florida Hospital Cancer Institute - Orlando
- Palm Beach Cancer Institute - West Palm Beach
Illinois
- MBCCOP - University of Illinois at Chicago - Chicago
- Veterans Affairs Medical Center - Chicago (Westside Hospital) - Chicago
- University of Chicago Cancer Research Center - Chicago
- Louis A. Weiss Memorial Hospital - Chicago
- West Suburban Center for Cancer Care - River Forest
District of Columbia
- Lombardi Cancer Center of Georgetown University Medical Center - Washington D.C.
- Walter Reed Army Medical Center - Washington D.C.
- Veterans Affairs Medical Center - Washington, DC - Washington D.C.
Alabama
- Northeast Alabama Regional Medical Center - Anniston
Delaware
- CCOP - Christiana Care Health Services - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2002-04 |
| Est. Completion | 2006-11 |
What the finished NCT00048971 record still lists
NCT00048971 is an observational study that tracks outcomes without assigning an intervention. The registered 308 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (80% lower).
The record links to 3 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which mutation analysis is the first listed.
NCT00048971 names 20 study sites across 6 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00048971 about?
NCT00048971 is a clinical study titled "Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy". RATIONALE: Genetic testing may help predict how patients will respond to chemotherapy drugs and may help doctors plan more effective treatment with fewer side effects. PURPOSE: Genetic study to determine how genes affect the severity of diarrhea in patients with stage III colon cancer who are recei...
What is the current status of trial NCT00048971?
This trial is currently completed. The enrollment target is 308 participants. The study started on 2002-04. Estimated completion is 2006-11.
What conditions does trial NCT00048971 study?
This clinical trial studies the following conditions: Colorectal Cancer, Diarrhea, Neutropenia.
What interventions are being tested in trial NCT00048971?
The interventions under investigation include: mutation analysis (GENETIC), polymorphic microsatellite marker analysis (GENETIC).
Who is sponsoring clinical trial NCT00048971?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00048971 being conducted?
This trial has 20 study locations across Alabama, California, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00048971's enrollment target sits among peer trials
308 107th of 381 higher than 275 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06090539 · 308 participants · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- NCT06233942 · 308 participants · Phase 1
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia